-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Benzinga·09/24/2026 12:21:02
Listen to the news
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.